# RayzeBio

开发针对SSTR2靶点的放射性药物疗法，用于治疗胃肠胰神经内分泌肿瘤，并运营印第安纳波利斯专用枢纽，实现其临床阶段RPT候选产品的端到端生产及按需交付。

Source: https://cn.bioecon.ru/companies/rayzebio/
Updated: 2026-07-03

- 国家: United States

## 可核验事实

| 事实 | 数值 | 来源 |
| --- | --- | --- |
| 融资 | 到 2022 年至少募集了 4.18亿美元股权资本，并计划于 2026 年投资 1.73亿美元扩大在印第安纳州的生产运营。 | https://rayzebio.com/rayzebio-advances-ryz101-a-targeted-radiopharmaceutical-delivering-actinium-225-into-clinical-development-for-two-cancer-indications/, https://trial.medpath.com/news/rayzebio-announces-173-million-investment-to-expand-radiopharmaceutical-manufacturing-in-indiana |
| 产能 | 设计在满负荷运行时每年生产数万剂。 | https://rayzebio.com/what-we-do/manufacturing/, https://trial.medpath.com/news/rayzebio-announces-173-million-investment-to-expand-radiopharmaceutical-manufacturing-in-indiana, https://www.bms.com/life-and-science/insights/new-rayzebio-hub-accelerates-next-gen-cancer-therapies.html, https://www.ibj.com/articles/drug-manufacturing-facility-offers-new-hope-in-cancer-fight |
| 生产基地 | 位于印第安纳州 Indianapolis 的现有 77,000 平方英尺设施；计划在印第安纳州 Boone County 新建 450,000 平方英尺的设施。 | https://rayzebio.com/what-we-do/manufacturing/, https://trial.medpath.com/news/rayzebio-announces-173-million-investment-to-expand-radiopharmaceutical-manufacturing-in-indiana, https://www.ibj.com/articles/drug-manufacturing-facility-offers-new-hope-in-cancer-fight |
| 员工人数 | 截至2025年7月约100名员工,计划到2029年底新增最多100个岗位。 | https://trial.medpath.com/news/rayzebio-announces-173-million-investment-to-expand-radiopharmaceutical-manufacturing-in-indiana, https://www.ibj.com/articles/drug-manufacturing-facility-offers-new-hope-in-cancer-fight |
| 营收 | $380 million（2024年）、$250 million（2023年）、$90 million（2022年）、$120 million（2021年）、$65 million（2020年） | https://www.privco.com/company/rayzebio, https://www.sec.gov/Archives/edgar/data/1825367/000162828023038595/ryzb-20230930.htm |

独立来源: bms.com, ibj.com, privco.com, sec.gov, trial.medpath.com

## 技术

- [放射性药物与诊疗一体化](https://cn.bioecon.ru/technology/radiopharmaceuticals-theranostics/)